Clinical Trial Update: Rilonacept to Improve Artery Function in Patients With Atherosclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rilonacept to improve artery function in patients with atherosclerosis completed, with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Coronary Artery Disease

Drugs mentioned

• Arcalyst (rilonacept)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Coronary Artery Disease, Atherosclerosis | Phase 2 | Status: COMPLETED | Results posted: 2010-04-13